Director Fred B. Davenport Jr. filed a Form 4 with the SEC on August 21, 2026, disclosing the exercise of three stock options and the sale of common stock in Medpace Holdings, Inc. (NASDAQ:MEDP) on August 19, 2026.
Key Highlights
- Three options exercised: Davenport exercised options covering 1,903 shares at $133.87, 3,858 shares at $84.36, and 1,822 shares at $164.68, all on August 19, 2026.
- Shares sold: 7,283 shares of common stock were disposed of on August 19, 2026, at a weighted average price of $606.15, with individual transactions ranging from $605.59 to $607.202.
- Remaining direct ownership: Following the transactions, Davenport directly held 3,798 shares of common stock.
- Indirect holdings: An additional 2,000 shares are held indirectly by a trust for the benefit of the reporting person.
- All options fully vested: The three exercised options had vested on May 18, 2023, May 13, 2021, and May 14, 2022, respectively, and each carried a post-exercise remaining balance of zero derivative securities.
Davenport's Option Exercises and Share Disposition at Medpace Holdings
According to the filing, Fred B. Davenport Jr., a director of Medpace Holdings, Inc., executed a series of transactions on August 19, 2026. He exercised three stock options using transaction code "M," acquiring 1,903 shares at an exercise price of $133.87, 3,858 shares at $84.36, and 1,822 shares at $164.68. The filing indicates each of these options had previously vested in full and that the price of each derivative security at exercise was $0, reducing all three option positions to zero following the transactions.
On the same date, the filing reports that Davenport disposed of 7,283 shares of common stock (transaction code "S") at a weighted average price of $606.15. The filing's footnote states that the shares were sold in multiple transactions ranging from $605.59 to $607.202 per share, and that the reporting person undertakes to provide full pricing information to the issuer, any security holder, or SEC staff upon request. Following all reported transactions, Davenport's direct beneficial ownership stood at 3,798 shares of common stock.
The filing also notes that 2,000 shares of common stock are held indirectly by a trust for the benefit of the reporting person. The Form 4 was signed by Stephen P. Ewald as attorney-in-fact for Fred B. Davenport Jr. and was filed on August 21, 2026.
What Was Disclosed
The filing disclosed the exercise of three vested stock options and the sale of 7,283 common shares by Medpace Holdings director Fred B. Davenport Jr. on August 19, 2026, leaving him with 3,798 directly held shares and 2,000 indirectly held shares.




Please wait processing your request...